Search hospitals > Texas > Houston
Center for Clinical Studies
Claim this profileHouston, Texas 77004
Global Leader in Psoriasis
Global Leader in Atopic Dermatitis
Conducts research for Eczema
Conducts research for Plaque Psoriasis
Conducts research for Genital Herpes
112 reported clinical trials
2 medical researchers
Summary
Center for Clinical Studies is a medical facility located in Houston, Texas. This center is recognized for care of Psoriasis, Atopic Dermatitis, Eczema, Plaque Psoriasis, Genital Herpes and other specialties. Center for Clinical Studies is involved with conducting 112 clinical trials across 39 conditions. There are 2 research doctors associated with this hospital, such as Stephen K Tyring, MD, PhD and Stephen Keith Tyring.Top PIs
Stephen K Tyring, MD, PhDSunpharma site no. 062 years of reported clinical research
Studies Arthritis
Studies Psoriatic Arthritis
7 reported clinical trials
8 drugs studied
Stephen Keith TyringCenter for Clinical Studies5 years of reported clinical research
Studies Atopic Dermatitis
Studies Eczema
4 reported clinical trials
4 drugs studied
Clinical Trials running at Center for Clinical Studies
Hidradenitis Suppurativa
Psoriasis
Atopic Dermatitis
Vitiligo
Plaque Psoriasis
Eczema
Acne
Scalp Psoriasis
Alopecia
Alopecia Areata
Subcutaneous Amlitelimab
for Hidradenitis Suppurativa
This is a parallel, Phase 2, 2-arm, double-blind, randomized, multicenter, multinational, placebo-controlled study to evaluate efficacy, safety, pharmacokinetics (PK), and biological effects of treatment of subcutaneous injection of amlitelimab compared with placebo in male and female participants aged 18 to 70 years with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to measure standardized clinician reported and participant-reported outcomes (ClinRO and PRO), safety, and drug concentration. An optional long-term extension (LTE) period will assess chronic safety and efficacy over an additional 80 weeks of amlitelimab treatment. Study details include: The study duration will be up to 116 weeks, including a 4-week Screening period, a 16-week double-blind treatment period (DBT), an optional 80-week LTE period and a 16-week post-treatment follow-up period. All participants who complete the 16-week DBT period will be offered entry into an optional LTE. Participants who do not wish to enter the optional LTE period or who stop treatment prior to Week 16 (Visit 6) or stop investigational medicinal product (IMP) administration prior to completing the LTE period will proceed into the 16-week post-treatment follow-up period. The number of planned in clinic visits will be up to six during the DBT period with an additional nine during the LTE period, plus one post-treatment follow-up end-of-study visit. Up to 11 optional in clinic visits are allowed for participants who do not wish to self-administer IMP between scheduled in clinic visits during the LTE period.
Recruiting0 awards Phase 24 criteria
SAR442970
for Hidradenitis Suppurativa
This is a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study is to evaluate the efficacy and safety of SAR442970 compared to placebo.
Recruiting0 awards Phase 28 criteria
Lutikizumab
for Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. Despite the clinical benefit anti-tumor necrosis factor (TNF) therapy offers to patients with HS, there remains a significant unmet medical need for patients who fail to achieve adequate benefit with anti-TNF therapy. This study will compare lutikizumab (ABT-981) versus placebo for the treatment of adult participants with moderate to severe HS who have failed anti-TNF therapy. Lutikizumab (ABT-981) is an investigational drug being developed for the treatment of HS. In the Main Study, participants will be put in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that participants will be assigned to placebo. Around 160 adult participants with moderate to severe HS who have failed anti-TNF therapy will be enrolled in the study at approximately 50 sites worldwide. In the Sub-study, participants will be put in 1 of 2 groups, called treatment arms. Both arms will receive treatment at different dosing intervals. Around 40 adult participants with moderate to severe HS who are naïve to biologic therapy will be enrolled in the study at certain sites. In the Main Study, participants will receive subcutaneous injections of lutikizumab (ABT-981) or placebo every week for 16 weeks. In the Sub-study, participants will receive subcutaneous injections of lutikizumab (ABT-981) every week for the first 15 weeks, then either every week or every other week for 36 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires and diaries.
Recruiting0 awards Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Center for Clinical Studies?
Center for Clinical Studies is a medical facility located in Houston, Texas. This center is recognized for care of Psoriasis, Atopic Dermatitis, Eczema, Plaque Psoriasis, Genital Herpes and other specialties. Center for Clinical Studies is involved with conducting 112 clinical trials across 39 conditions. There are 2 research doctors associated with this hospital, such as Stephen K Tyring, MD, PhD and Stephen Keith Tyring.